Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000976
Status:
COMPLETED
Last Update Posted:
2008-08-06
First Post:
1999-11-02
Brief Title:
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G rCD4-IgG Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Organization Data
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Class:
NIH
Study ID:
ACTG 134
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |